| Title |
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
|
| Creator |
Dufva Olli
Kankainen Matti
Kelkka Tiina
Sekiguchi Nodoka
Awad Shady Adnan
Eldfors Samuli
Yadav Bhagwan
Kuusanmaki Heikki
Malani Disha
Andersson Emma I.
Pietarinen Paavo
Saikko Leena
Kovanen Panu E.
Ojala Teija
Lee Dean A.
Loughran Thomas P. Jr.
Nakazawa Hideyuki
Ko Young Hyeh
Kim Won Seog
Chuang Shih-Sung
Aittokallio Tero
Chan Wing C.
Ohshima Koichi
Ishida Fumihiro
Mustjoki Satu
|
| Source Title |
NATURE COMMUNICATIONS
|
| Volume | 9 |
| Journal Identifire |
ISSN 2041-1723
|
| Language |
eng
|
| Resource Type | journal article |
| Publisher |
NATURE PUBLISHING GROUP
|
| Date of Issued | 2018-04-19 |
| Access Rights | metadata only access |
| Relation |
[DOI] 10.1038/s41467-018-03987-2
[PMID] 29674644
|
| Remark | We thank the staff of High Throughput Biomedicine (Laura Turunen, Maria Nurmi, Jani Saarela) and Sequencing Laboratory (Pekka Ellonen, Sari Hannula, Aino Palva, Pirkko Mattila) Units at the Institute of Molecular Medicine Finland (FIMM) and Judith Klievink and other personnel of Hematology Research Unit Helsinki for their excellent technical assistance. We thank Dr. I-Ming Chen for kindly providing the IMC-1 cell line and Dr. Norio Shimizu for originally providing the SNK-6 cell line. This work was supported by the European Research Council (M-IMM project), Academy of Finland (grant no. 292605 and 287224), Tekes - the Finnish Funding Agency for Innovation (Dnro 6113/31/2016), Finnish special governmental subsidy for health sciences, research and training, the Sigrid Juselius Foundation, the Instrumentarium Science foundation, the Cancer Society of Finland, and the Finnish Cancer Institute. W.C.C. receives support from the City of Hope Cancer Center Support Grant (P30CA33572) and Lymphoma SPORE developmental project grant (1 P50 CA 136411-01 01A1 PP-4). F.I. was supported by KAKEN 15K09471 from Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Leukemia Research Fund; Takeda Pharmaceutical (inst); Cyugai Pharmaceutical (inst); Kyowa Hakko-Kirin (inst) and Pfizer (inst). The authors would like to thank the Exome Aggregation Consortium and the groups that provided exome variant data for comparison. A full list of contributing groups can be found at http://exac.broadinstitute.org/about. |
